We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The mounting safety concerns swirling around the pharmaceutical industry are
beginning to have a profound effect on the American public's perception of drug
companies, according to a recent online poll.
Drugmaker Lex Pharmaceutical has been issued a warning letter
following an FDA inspection that revealed a slew of manufacturing violations
at the company's Medley, Fla., plant.
The new chairman of the Senate Health, Education, Labor and Pensions (HELP)
Committee said he would support legislation allowing the importation of pharmaceuticals
into the U.S., but noted that such a plan could conflict with the mission of
the FDA.
Two new clinical studies provide further evidence that the use of anti-inflammatory
Cox-2 inhibitor drugs could increase the risk of serious cardiovascular events
in humans.
AEterna Zentaris has announced the closing of the acquisition of all Multichem
assets by its subsidiary Atrium Biotechnologies for the total amount of $23.8
million of which $22.2 million were paid in cash at the closing.
Sciona, a private, international biotechnology company, is moving its headquarters
from the UK to Boulder, Colo. Jim Bruce, a Boulder businessman, has been named
CEO.
Applied DNA Sciences has reported that its managing investment banker, New York-based
Vertical Capital Partners along with participation from other funds and investors,
has closed on $5,482,993 of funding for APDN.
Pall has acquired Euroflow (UK) of Stroud, England. The company is one of the
world's leading manufacturers of pilot and production scale chromatography columns
for the biotechnology industry.
Protein Design Labs has agreed to buy the hospital-focused pharmaceutical firm
ESP Pharma for $300 million in cash and roughly $175 million in stock, thereby
gaining marketed products, a 75-person sales force, entry into the cardiac field
-- and approximately $14 million in ESP debt.
Genaissance Pharmaceuticals, a leading developer and user of genetic information
to help guide medical therapy, expanded its ability to provide genetic tests
for critical variants of key cardiac ion channel proteins involved in drug-induced
cardiac arrhythmias.
Genetronics Biomedical, a late stage developer of oncology and other therapies
using electroporation to deliver drugs and nucleic acids, has announced the
acquisition of Oslo-based Inovio AS, a leader in patented gene delivery technology
for the most efficient, nonviral method for gene transfer to skeletal muscles.